Completed PHASE2 INTERVENTIONAL 3-arm NCT00813072

Study of PEP02, Irinotecan or Docetaxel in Gastric or Gastroesophageal Junction Adenocarcinoma

A Randomized Phase II Study of PEP02, Irinotecan or Docetaxel as a Second Line Therapy in Patients With Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Sponsor: PharmaEngine

Conditions Esophageal Neoplasms Stomach Neoplasms

Interventions PEP02 docetaxel irinotecan

Updated 7 times since 2017 Last updated: Mar 1, 2012 Started: Nov 30, 2007 Primary completion: Jul 31, 2010 Completion: Dec 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Esophageal Neoplasms and Stomach Neoplasms and is currently completed. PharmaEngine leads this study, which shows 7 recorded versions since 2007 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

7 versions recorded

Dec 2025 — Present [monthly]

Completed PHASE2
Sep 2025 — Dec 2025 [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Nov 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

PharmaEngine

Data source: PharmaEngine

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Barcelona, Spain , Cambridge, United Kingdom , Chiayi City, Taiwan , Elche, Spain , Linkou District, Taiwan , London, United Kingdom , Madrid, Spain , Maidstone, United Kingdom , Mostar, Bosnia and Herzegovina , Rijeka, Croatia and 8 more locations